Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease

Atherosclerosis

Volumn 253, Issue , 2016, Pages 135-143

  Anguiano, Lidia ^a   Riera, Marta ^a   Pascual, Julio ^a   Valdivielso, José Manuel ^b   Barrios, Clara ^a   Betriu, Angels ^b,c   Clotet, Sergi ^a   Mojal, Sergi ^d   Fernández, Elvira ^b,c   Soler, María José ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Cardiovascular disease; Chronic kidney disease; Circulating ACE2; Subclinical atherosclerosis

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CREATININE; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGE DISTRIBUTION; AGED; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SMOKING; BLOOD; CAROTID ARTERY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETIC COMPLICATION; FEMORAL ARTERY; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; BIOMARKERS; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES COMPLICATIONS; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84986317416     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.08.032     Document Type: Article

References (43)

1. [1] Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42 (2003), 1050–1065.
2. [2] Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E., Hsu, C., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351 (2004), 1296–1305.
3. [3] Tonelli, M., Isles, C., Curhan, G.C., Tonkin, A., Pfeffer, M.A., Shepherd, J., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004), 1557–1563.
4. [4] Keith, D.S., Nichols, G.A., Gullion, C.M., Brown, J.B., Smith, D.H., Longitudinal Follow-up and Outcomes Among a Population with Chronic Kidney Disease in a Large Managed Care Organization, vol. 164, 2015, 659–663.
5. [5] Simon, A., Megnien, J.L., Chironi, G., The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 182–185.
6. [6] Rubin, M.F., Rosas, S.E., Chirinos, J.A., Townsend, R.R., Surrogate markers of cardiovascular disease in CKD: what's under the hood?. Am. J. Kidney Dis. 57 (2011), 488–497.
7. [7] Weber, C.I.K., Duchateau-Nguyen, G., Solier, C., Schell-Steven, A., Hermosilla, R., Nogoceke, E., et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4. Clin. Kidney J. 7 (2014), 167–173.
8. [8] Recio-Mayoral, A., Banerjee, D., Streather, C., Kaski, J.C., Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease - a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 216 (2011), 446–451.
9. [9] Kato, A., Takita, T., Maruyama, Y., Kumagai, H., Hishida, A., Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int. 64 (2003), 1472–1479.
10. [10] Kim, J.-K., Song, Y.R., Kim, M.G., Kim, H.J., Kim, S.G., Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients. BMC Cardiovasc Disord., 13, 2013, 96.
11. [11] Junyent, M., Martínez, M., Borràs, M., Coll, B., Valdivielso, J.M., Vidal, T., et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol., 11, 2010, 14.
12. [12] Junyent, M., Martínez, M., Borrás, M., Bertriu, A., Coll, B., Craver, L., et al. Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project. Nefrol Publicación Of La Soc Española Nefrol 30 (2010), 119–126.
13. [13] Betriu, A., Martinez-Alonso, M., Arcidiacono, M.V., Cannata-Andia, J., Pascual, J., Valdivielso, J.M., et al. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrol. Dial. Transpl. 29 (2014), 1415–1422.
14. [14] Arroyo, D., Betriu, A., Martinez-Alonso, M., Vidal, T., Valdivielso, J.M., Fernández, E., Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol., 15, 2014, 168.
15. [15] Dzau, V., The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J. Hypertens. Suppl. 23 (2005), S9–S17.
16. [16] Velez, J.C.Q., The importance of the intrarenal renin-angiotensin system. Nat. Clin. Pract. Nephrol. 5 (2009), 89–100.
17. [17] Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87 (2000), E1–E9.
18. [18] Santos, R.A.S., Simoes e Silva, A.C., Maric, C., Silva, D.M.R., Machado, R.P., de Buhr, I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 8258–8263.
19. [19] Lambert, D.W., Yarski, M., Warner, F.J., Thornhill, P., Parkin, E.T., Smith, A.I., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280 (2005), 30113–30119.
20. [20] Rice, G.I., Jones, A.L., Grant, P.J., Carter, A.M., Turner, A.J., Hooper, N.M., Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48 (2006), 914–920.
21. [21] Lew, R.A., Warner, F.J., Hanchapola, I., Yarski, M.A., Ramchand, J., Manohar, J., et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp. Physiol. 93 (2008), 685–693.
22. [22] Epelman, S., Tang, W.H.W., Chen, S.Y., Van Lente, F., Francis, G.S., Sen, S., Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J. Am. Coll. Cardiol. 52 (2008), 750–754.
23. [23] Ortiz-Pérez, J.T., Riera, M., Bosch, X., De Caralt, T.M., Perea, R.J., Pascual, J., et al. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS One, 8, 2013, e61695.
24. [24] Soro-Paavonen, A., Gordin, D., Forsblom, C., Rosengard-Barlund, M., Waden, J., Thorn, L., et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J. Hypertens. 30 (2012), 375–383.
25. [25] Soler, M.J., Riera, M., Crespo, M., Mir, M., Márquez, E., Pascual, M.J., et al. Circulating angiotensin-converting enzyme 2 activity in kidney transplantation: a longitudinal pilot study. Nephron. Clin. Pract. 121 (2012), c144–150.
26. [26] Roberts, M.A., Velkoska, E., Ierino, F.L., Burrell, L.M., Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. Nephrol. Dial. Transpl. 28 (2013), 2287–2294.
27. [27] Anguiano, L., Riera, M., Pascual, J., Valdivielso, J.M., Barrios, C., Betriu, A., et al. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol. Dial. Transpl. 30 (2015), 1176–1185.
28. [28] Zhang, C., Zhao, Y.X., Zhang, Y.H., Zhu, L., Deng, B.P., Zhou, Z.L., et al. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 15886–15891.
29. [29] Zhang, Y.-H., Zhang, Y., Dong, X.-F., Hao, Q.-Q., Zhou, X.-M., Yu, Q.-T., et al. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm. Res. 64 (2015), 253–260.
30. [30] Dong, B., Zhang, C., Feng, J.B., Zhao, Y.X., Li, S.Y., Yang, Y.P., et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 1270–1276.
31. [31] Thatcher, S.E., Zhang, X., Howatt, D.A., Lu, H., Gurley, S.B., Daugherty, A., et al. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 758–765.
32. [32] Thomas, M.C., Pickering, R.J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 107 (2010), 888–897.
33. [33] Riera, M., Anguiano, L., Clotet, S., Roca-Ho, H., Rebull, M., Pascual, J., et al. Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. Am. J. Physiol. Ren. Physiol. 310 (2016), F534–F546.
34. [34] Wysocki, J., Ye, M., Soler, M.J., Gurley, S.B., Xiao, H.D., Bernstein, K.E., et al. ACE and ACE2 activity in diabetic mice. Diabetes 55 (2006), 2132–2139.
35. [35] Gracia, M., Betriu, A., Martinez-Alonso, M., Arroyo, D., Abajo, M., Fernandez, E., et al. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin. J. Am. Soc. Nephrol., 2015, 1–10.
36. [36] Barrios, C., Pascual, J., Otero, S., Soler, M.J., Rodríguez, E., Collado, S., et al. Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. Atherosclerosis 242 (2015), 37–44.
37. [37] Martín, M., Valls, J., Betriu, A., Fernández, E., Valdivielso, J.M., Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference. Atherosclerosis 241 (2015), 264–270.
38. [38] Epelman, S., Shrestha, K., Troughton, R.W., Francis, G.S., Sen, S., Klein, A.L., et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J. Card. Fail 15 (2009), 565–571.
39. [39] Riera, M., Márquez, E., Clotet, S., Gimeno, J., Roca-Ho, H., Lloreta, J., et al. Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. PLoS One, 9, 2014, e84683.
40. [40] Oudit, G.Y., Kassiri, Z., Patel, M.P., Chappell, M., Butany, J., Backx, P.H., et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 75 (2007), 29–39.
41. [41] Zulli, A., Burrell, L.M., Widdop, R.E., Black, M.J., Buxton, B.F., Hare, D.L., Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J. Histochem Cytochem 54 (2006), 147–150.
42. [42] Sluimer, J.C., Gasc, J.M., Hamming, I., van Goor, H., Michaud, A., van den Akker, L.H., et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J. Pathol. 215 (2008), 273–279.
43. [43] Lovren, F., Pan, Y., Quan, A., Teoh, H., Wang, G., Shukla, P.C., et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 295 (2008), H1377–H1384.